Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-08

Clinical Trial Update: Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating silymarin for non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Silymarin (silymarin)

Snippet

Sponsor: University of Malaya | Conditions: Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED